Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
-- Ablexis Looks Forward to Establishing Additional Non-Exclusive Partnerships in 2017 --
BURLINGAME, Calif., Feb. 14, 2017 -- Ablexis, LLC today announced a licensing agreement for its AlivaMab Mouse technology with Janssen Biotech, Inc. (Janssen). The perpetual, non-exclusive license provides Janssen access to the AlivaMab Mouse platform and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. Ablexis will receive an eight-figure up-front payment.
“Ablexis is pleased to add Janssen to the growing list of companies that have licensed the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “This license further affirms the recognition by the world’s leading pharmaceutical companies of the power of the AlivaMab Mouse for rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability. Ablexis remains dedicated to making the AlivaMab Mouse broadly available for antibody drug discovery through flexible partnering strategies.”
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple global pharmaceutical companies and continues making the AlivaMab Mouse available via non-exclusive licenses. The company was founded in 2009 and is based in Burlingame, California; more information can be found by visiting the Company’s website at www.ablexis.com.
Ablexis Corporate Contact: Ablexis, LLC Larry Green, (415) 967-1220 [email protected] Ablexis Media Contact: Red House Communications Denise Powell, (510) 703-9491 [email protected]
